TRISALUS LIFE SCIENCES INC (TLSI) Fundamental Analysis & Valuation

NASDAQ:TLSI • US89680M1018

4.465 USD
-0.3 (-6.39%)
At close: Mar 6, 2026
4.39 USD
-0.08 (-1.68%)
After Hours: 3/6/2026, 8:00:02 PM

This TLSI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, TLSI scores 2 out of 10 in our fundamental rating. TLSI was compared to 519 industry peers in the Biotechnology industry. Both the profitability and financial health of TLSI have multiple concerns. TLSI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. TLSI Profitability Analysis

1.1 Basic Checks

  • In the past year TLSI has reported negative net income.
  • In the past year TLSI has reported a negative cash flow from operations.
  • In multiple years TLSI reported negative net income over the last 5 years.
  • In the past 5 years TLSI always reported negative operating cash flow.
TLSI Yearly Net Income VS EBIT VS OCF VS FCFTLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • TLSI has a Return On Assets of -198.16%. This is amonst the worse of the industry: TLSI underperforms 88.25% of its industry peers.
Industry RankSector Rank
ROA -198.16%
ROE N/A
ROIC N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSI Yearly ROA, ROE, ROICTLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • TLSI's Gross Margin of 84.04% is amongst the best of the industry. TLSI outperforms 87.28% of its industry peers.
  • TLSI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSI Yearly Profit, Operating, Gross MarginsTLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

2

2. TLSI Health Analysis

2.1 Basic Checks

  • TLSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TLSI Yearly Shares OutstandingTLSI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
TLSI Yearly Total Debt VS Total AssetsTLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -10.78, we must say that TLSI is in the distress zone and has some risk of bankruptcy.
  • TLSI's Altman-Z score of -10.78 is on the low side compared to the rest of the industry. TLSI is outperformed by 74.18% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.78
ROIC/WACCN/A
WACC8.64%
TLSI Yearly LT Debt VS Equity VS FCFTLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • TLSI has a Current Ratio of 3.05. This indicates that TLSI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of TLSI (3.05) is worse than 64.16% of its industry peers.
  • A Quick Ratio of 2.75 indicates that TLSI has no problem at all paying its short term obligations.
  • TLSI's Quick ratio of 2.75 is on the low side compared to the rest of the industry. TLSI is outperformed by 65.13% of its industry peers.
Industry RankSector Rank
Current Ratio 3.05
Quick Ratio 2.75
TLSI Yearly Current Assets VS Current LiabilitesTLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

4

3. TLSI Growth Analysis

3.1 Past

  • TLSI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.56%, which is quite impressive.
EPS 1Y (TTM)22.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.91%

3.2 Future

  • The Earnings Per Share is expected to grow by 48.59% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 35.24% on average over the next years. This is a very strong growth
EPS Next Y76.03%
EPS Next 2Y48.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year40.05%
Revenue Next 2Y40.9%
Revenue Next 3Y38.65%
Revenue Next 5Y35.24%

3.3 Evolution

TLSI Yearly Revenue VS EstimatesTLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
TLSI Yearly EPS VS EstimatesTLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

1

4. TLSI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TLSI. In the last year negative earnings were reported.
  • Also next year TLSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSI Price Earnings VS Forward Price EarningsTLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSI Per share dataTLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • TLSI's earnings are expected to grow with 48.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.59%
EPS Next 3YN/A

0

5. TLSI Dividend Analysis

5.1 Amount

  • No dividends for TLSI!.
Industry RankSector Rank
Dividend Yield 0%

TLSI Fundamentals: All Metrics, Ratios and Statistics

TRISALUS LIFE SCIENCES INC

NASDAQ:TLSI (3/6/2026, 8:00:02 PM)

After market: 4.39 -0.08 (-1.68%)

4.465

-0.3 (-6.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-18
Inst Owners19.34%
Inst Owner Change11.46%
Ins Owners15.17%
Ins Owner Change9.42%
Market Cap267.05M
Revenue(TTM)N/A
Net Income(TTM)-72.25M
Analysts83.08
Price Target11.73 (162.71%)
Short Float %4.14%
Short Ratio6.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.04%
Min EPS beat(2)-64.97%
Max EPS beat(2)-21.11%
EPS beat(4)0
Avg EPS beat(4)-45.86%
Min EPS beat(4)-73.8%
Max EPS beat(4)-21.11%
EPS beat(8)3
Avg EPS beat(8)-21.42%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.38%
Min Revenue beat(2)-3.58%
Max Revenue beat(2)2.81%
Revenue beat(4)1
Avg Revenue beat(4)-0.37%
Min Revenue beat(4)-3.58%
Max Revenue beat(4)2.81%
Revenue beat(8)4
Avg Revenue beat(8)0.75%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.04%
EPS NY rev (1m)0.1%
EPS NY rev (3m)-3.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.64
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.67
BVpS-0.45
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -198.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.04%
FCFM N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 132.85%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.05
Quick Ratio 2.75
Altman-Z -10.78
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y76.03%
EPS Next 2Y48.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.91%
Revenue Next Year40.05%
Revenue Next 2Y40.9%
Revenue Next 3Y38.65%
Revenue Next 5Y35.24%
EBIT growth 1Y26.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.06%
EBIT Next 3Y28.55%
EBIT Next 5Y21.3%
FCF growth 1Y47.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.68%
OCF growth 3YN/A
OCF growth 5YN/A

TRISALUS LIFE SCIENCES INC / TLSI FAQ

What is the fundamental rating for TLSI stock?

ChartMill assigns a fundamental rating of 2 / 10 to TLSI.


What is the valuation status of TRISALUS LIFE SCIENCES INC (TLSI) stock?

ChartMill assigns a valuation rating of 1 / 10 to TRISALUS LIFE SCIENCES INC (TLSI). This can be considered as Overvalued.


What is the profitability of TLSI stock?

TRISALUS LIFE SCIENCES INC (TLSI) has a profitability rating of 1 / 10.


What is the earnings growth outlook for TRISALUS LIFE SCIENCES INC?

The Earnings per Share (EPS) of TRISALUS LIFE SCIENCES INC (TLSI) is expected to grow by 76.03% in the next year.